#class action lawsuit #securities litigation #Aardvark Therapeutics

Significant Stock Decline for Aardvark Therapeutics

Aardvark Therapeutics, Inc., trading under NASDAQ symbol AARD, has recently attracted attention due to a drastic decline in its stock value following critical disclosures made by the company. Within just a short span, the shares lost over 70% of their initial public offering (IPO) price, raising serious concerns among investors. This stock drop has prompted Levi & Korsinsky, LLP to alert stakeholders about an impending securities class action lawsuit.

Timeline of Events

The troubles for Aardvark began soon after its February 2025 IPO, where shares were initially priced at $16.00. Subsequently, between February 13, 2025, and May 14, 2026, significant announcements rattled investor confidence:

1. February 27, 2026: Aardvark announced a voluntary pause in its Phase 3 HERO trial. The company cited “reversible cardiac observations” discovered during routine safety monitoring of a healthy volunteer study as the reason for this precaution. Investors reacted swiftly, leading to a sharp decline in share prices.

2. May 14, 2026: The company informed investors that the FDA had imposed a full clinical hold on its investigational new drug application for ARD-101. This hold impacted both the Phase 3 HERO trial and its open-label extension. With these revelations, investors began to question the earlier communications from Aardvark that suggested ARD-101 was